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INTRODUCTION 
Heart failure(HF) is a debilitating and generally lethal 
condition responsible for enormous burden on health care. 
HF is one of the most common causes of admission in the 
emergency department. Prevalence of HF is increasing in 
our society and is the cause of poor quality of life and 
premature death. Approximately 5 million people in the 
United States have been diagnosed with HF and about 
550,000 new cases are diagnosed annually1. Heart failure 
carries a 50 % mortality at 5 years after symptom onset2.  
One third of the patients with most severe disease die 
within the first year after diagnosis3 .  Prevalence of 
congestive heart failure (CHF) , 18.8million (1.76% of 
population) and incidence 1.57 million/ year(0.15%)has 
been reported in India4.  Incidence approaches 10 per 1000 
in people older than 65 years. Prognosis of HF depends on 
age, left ventricular ejection fraction (LVEF)5,  plasma 
norepinephrine,β type natriuretic peptide(BNP)levels, 
ECG ,evidence of left ventricular hypertrophy6.,  atrial 
fibrillation, renal functions7 and presence of ventricular 
dysrrhythmias. 
  HF is a progressive disease characterized by adaptive 
neurohumoral activation of rennin angiotensin aldosterone 
system(RAAS) ,sympathetic nervous system, natriuretic 
peptides, endothelin, vasopressin and other regulatory 
mechanisms. Inflammatory mediators are also involved in 
the pathogenesis of chronic heart failure8. Management of 
patients with HF remains a challenging problem. Despite 
advances in the management, heart failure patients have 
high mortality and  deaths due to HF have increased  by 
145% over the last 2 decades. There is no cure for this 
condition.  
 Anemia is common in patients with HF and is associated 
with more severe symptoms9, lower functional status, 
worse exercise capacity9,cognitive impairment and worse 
quality of life. Preliminary open label studies in systolic 
HF have suggested that treatment with erythropoiesis 
stimulating agents leads to improvement in NYHA class, 
exercise capacity, cardiac and renal functions10. Anker et al 
11 demonstrated that treatment with intravenous ferric 
carboxymaltose in patients with chronic HF improves 
symptoms, functional capacity and quality of life. 
Intravenous iron sucrose has also been shown to improve 
exercise capacity in anemic patients with CHF12. On the 
other hand Ghali et al 13demontrated that treatment with 
darbepoietin alpha was not associated with significant 
clinical benefit in patients with symptomatic HF. Recently, 
four clinical trials treating anemia in HF with 
erythropoiesis stimulating agents in Europe were stopped 
prematurely because of increased mortality in 
erythropoietin treated patients14. In view of the conflicting 
reports available and no oral iron preparations were used to 
correct anemia in HF patients, the present study was 
undertaken to evaluate effect of oral iron supplementation 
on functional status and clinical outcomes in patients with 
heart failure. 
METHODS 
This was  a prospective controlled, open labelled and 
comparative clinical study conducted at PGIMS-
Rohtak(Haryana) India. An informed written consent was 
taken from all patients. Total 60 patients of either sex 
diagnosed with anemia in HF were enrolled for the study. 
Patients who were eligible as per inclusion and exclusion 
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criteria were allocated to receive one of the two different 
treatments in an open fashion and subjected to  clinical 
assessment including efficacy and safety. Inclusion 
criteria—Patients of either sex aged >18 years, heart 
failure NYHA class II & III, exercise tolerance in the form 
of walk, 6- min.  walk distance of < 375meters, LVEF <40 
%,and Hb level 8-11g/dl. Exclusion criteria—Patients with 
severe infection within 1 month, uncorrected primary 
valvular disease, active myocarditis or constrictive 
pericarditis , patients with history of cardiac arrest or 
sustained ventricular tachycardia or fibrillation, within the 
previous year,  patients with unstable angina or acute 
myocardial infarction, cardiac revascularization procedure 
or stroke . Patients with severe pulmonary, renal or hepatic 
disease, history of allergy to iron and systolic BP 
<85mmHg or > 160 mmHg, diastolic BP > 89 mmHg. 
Study Design—After screening, patients were divided in 
to 2 groups of 30 each. Group –I-Patients with anemia (Hb 
8-11g/dl) with HF(NYHA class II &III) were given  oral 
iron ,ferrous sulfate 100mg,twice daily for 3 months along  
with standard treatment for HF. Group- II- Patients of 
anemia with HF were given standard treatment  of HF like 
ACE inhibitors(ramipril 5mg/day),  diuretics (furosemide 
60mg/day), inotropic agents (digoxin 0.25 mg/day for 5 
days in a week ), vasodilators (nitrates- glyceryltrinitrate 
2.6 mg, twice daily) and hypolipidemic drugs( 
atorvastatin20mg/ day) etc was  not interrupted in both the 
groups.  
End Points 
The primary end point of the study was exercise 
tolerance/capacity, 6 min walk distance15. This test 
measures the distance( in meters) that a patient can quickly 
walk on a flat, hard surface in a period of 6 minutes quality 
of life- Minnesota Living with Heart Failure 
Questionnaire(MLHFQ)16  and haematological parameters 
( Hb, peripheral blood film& reticulocyte count). 
Secondary end point of the study was Borg scale for 
dyspnoea and fatigue17, efficacy assessment for anemia ( 
signs and symptoms) and haematological parameters 
endpoints like mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH), MCHC, packed cell 
volume (PCV),reticulocyte count (RC) and  RBC count. 
Cell counter method18 was used to assess Hb, MCV,MCH, 
MCHC, PCV,and RBC count. 
Safety assessment 
Patients were assessed for side effects of oral iron therapy 
before treatment and after 15, 45 and 90 days of iron 
treatment. Any other adverse effects reported by the 
patients were recorded. 
Statistical analysis- In the descriptive analysis, mean and 
standard error of mean (SEM) of demographic and various 
clinical parameters were calculated. Among analytic 
Statistical technique repeated measures ANOVA test was 
applied for intragroup analysis and independent‘ t’ test was 
applied for intergroup analysis. Incidence of microcytic 
hypochromic anemia on peripheral blood film was tested 
using chi square test. A  p value<0.05 was considered as 
statistically significant. 
RESULTS 
Total 95 HF patients were screened. Out of these 26 
patients were excluded as they did not match predefined 
inclusion criteria. Only 60 patients completed the study 
and rest were lost to follow up. The baseline characterstics 
of the study population are as, mean age in group I and II, 
55.63±1.73 and 57.73 ±2.38 respectively. M/F - 23/7 (I) & 
22/8 (II).  
Primary end points Exercise tolerance/capacity- Six min. 
walk distance in group I and II, before treatment was 
comparable. There was significant increase in 6 min. walk 
distance after 45 and 90 days of oral iron treatment in 
group I , whereas increase in 6 min. walk distance in group 
II was observed only after 90 days. Although, there was 
improvement in exercise tolerance in both groups but 
improvement was observed earlier in iron treated group. 
(table 1) 
Quality of life- There was significant decrease in MLHFQ 
score after 90 days of iron treatment in group I and group 
II as compared to pretreatment values.  Improvement was 
seen in both the groups but more marked in iron treated 
groups  
Haematological parameters- Haemoglobin(Hb)-  There 
was significant increase in Hb  value after 15, 45 and 90 
days of oral iron treatment as compared to control (group 
II). 
Peripheral blood film (PBF)- There was reduced 
incidence of microcytic hypochromic anemia after 45 and 
90 days of oral iron treatment as compared to group II.  
Reticulocyte count- There was significant increase in 
reticulocyte count after 15, 45 and 90 days of oral iron 
treatment (group I ) as compared to group II.  
Secondary end points- Borg scale for dyspnoea- As 
shown in table -2 ,there was significant decrease in Borg 
dyspnoea score after 45 and 90 days of oral iron 
supplementation (group I). However, decreased score was 
also noted in group II but only after 90 days. There was 
improvement of dyspnoea in both groups but was earlier 
and more marked in group I receiving oral iron treatment. 
Table 1:Effect of oral iron supplementation on exercise tolerance/capacity, 6-min. walk distance(m) in anemic 
patients with heart failure. 
Groups            Before                                             After iron treatment 
                                                                   15  Days                       45 Days                   90  Days 
I                        330.87±5.01        331.40±4.81             336.50±5.08*            347.03±4.73* 
II                       325.70±5.05       326.30±4.57             328.43±5.73             332.07±5.23* @ 
------------------------------------------------------------------------------------------------------------------------------------------*  
p<0.001 when compared with pretreatment values (Student’s  ‘ t’ test),   @ p< 0.05 when compared with group I (ANOVA)  
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Table- 2 : Effect of oral iron supplementation on Borg dyspnoea and fatigue score in anemic patients with heart 
failure. Data presented as Mean±SEM. 
Groups             Pretreatment                                              After iron treatment 
                                                                 15  Days                   45  Days                 90  Days 
                                                            Borg   Dyspnoea    Score 
        I                    7.23± 0.22               7.06± 0.22                 6.16±0.20*                4.73± 0.21* 
        II                    7.03±0.27                7.00±0.26                 6.46±0.25                  5.86±0.28 * @ 
                                                              Borg   Fatigue   Score 
          I                     6.83±0.25                6.53± 0.22               5.96±0.22                    5.03  ±0.17* 
         II                    7.00± 0.29                6.73 ±0.27               6.13± 0.26                   5.86±0.29* # 
 P < 0.001 when compared with pretreatment(Student’s  ‘t’ test), @ p<0.01, # p>0.05 when compared with group I (ANOVA). 
Borg scale for fatigue- As shown in table-2 ,there was 
more improvement in fatigue in iron treated patients as 
compared to group II.  
Haematological parameters—Mean corpuscular volume 
(MCV) There was  significant increase in MCV 
,MCH,MCHC,PCV and RBC count values after 15, 45 and 
90 days of iron treatment(group-I) as compared to 
control(group- II) .( Table-3). Signs and symptoms of 
anemia- The incidence of fatigability and pallor gradually 
reduced after iron therapy. Total number of patients 
complaining fatigue before treatment were 29, while after 
15 , 45 and 90 days of iron treatment  number of patients 
were 29, 21 and 14  respectively(group-I). In control 
group, there was no improvement in this parameter.  In 
iron treated patients pallor was also gradually reduced, 
while it remained same or even increased in control group.  
 
Table 3 : Effect of oral iron treatment on haematological parameters in anemic patients with heart failure. 
Groups     Parameters       Before                                      After  Treatment 
                                                                            15 Days                              45 Days                           90 Days 
     I            Hb(g/dl)             10.03±0.12         10.07±0.12                        10.50±0.14                    11.17±0.18* 
     II             -do-                    9.94±0.14            9.92±0.14                        9.83± 0.14                    9.72± 0.14** 
      I            PBF                       16                           16                                     15                                      11 
       II           - do-                      17                          17                                      17                                    19 @ 
     I            R C  ( % )              0.58±0.01            0.62±0.01*                         0.71±0.01*                   0.81 ±0.01* 
     II           -do-                       0.57±0.01            0.56± 0.01**                       0.56±0.01**               0.55± 0.01**# 
      I           MCV (fl)               86.14±1.11          86.27±1.11                       87.07±1.11 *               88.30±1.11* 
     II           -do-                       85.63±1.23          85.59± 1.23**                    85.44±1.23 **             84.86± 1.23**# 
      I           MCH(pg)              24.37±1.54         24.47±0.29                         24.80 ±0.28               25.38±0.29* 
       II           -do--                   24.43± 1.60        24.40±0.29 **                     24.27±0.29 **             24.10± 0.30**# 
       I          MCHC(g/dl)         28.40±0.42         28.51±0.42                        28.91 ± 0.42               29.50±0.42* 
       II            -do-                   28.60±0.35          28.56±0.35**                     28.41± 0.35**             28.21±0.35**# 
        I          PCV (%)             35.60±0.47          35.63±0.46                        36.33±0.47 *               37.23±0.48* 
       II         - do--                    34.93±0.51          34.90±0.51**                     34.86±0.52**              34.57±0.54**# 
        I          RBCcount            4.14±0.05            4.19 ±0.05                        4.33±0.05*                  4.49±0.05* 
       II          --do-                    4.09±0.06            4.06±0.06**                       4.00±0.06**                 3.93±0.06**# 
------------------------------------------------------------------------------------------------------------------------------------------*           
p  <0.001, ** p >0.05 when compared with pretreatment value (Student’s ‘t’ test), @ p<0.05 when compared to group  I(chi-square test), # p<0.05 when 
compared with group I (ANOVA). 
PBE-peripheral blood film, RC-reticulocyte count, MCV- mean corpuscular volume, MCH –mean corpuscular  haemoglobin, MCHC-mean corpuscular 
haemoglobin concentration, PCV-packed cell volume RBC- red blood cell. 
 
Safety assessment- Orally administered ferrous sulfate 
was well tolerated with few mild side effects.  In iron 
treated group, out of 30 patients 5patients reported with 
epigastric pain and heart burn, 4-nausea, 2- diarrhea, 2- 
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constipation and 1 patient with metallic taste, while none 
of these side effects were observed in group II patients.  
DISCUSSION 
Present study revealed that oral iron administration in HF  
patients with anemia improved exercise tolerance as 
measured by 6- min.  walk distance, quality of life as 
measured by MLHFQ, Borg dyspnoea and fatigue score 
and various haematological parameters such as Hb,PBF, 
MCV, MCHC,PCV and RBC count. These results indicate 
significant improvement in clinical outcomes and health 
related quality of life after oral iron therapy in anemic 
patients with heart failure. Beneficial effects of iron 
therapy may be due to improved cardiac function like left 
ventricular  ejection fraction (LVEF) or decreased 
ventricular hypertrophy, increased delivery of oxygen to 
heart muscle and aerobic metabolism, decreased 
production of inflammatory cytokines like tumor necrosis 
factor-α (TNF-α ) and anti-apoptotic effect. Our finding 
are in agreement with previous studies to some extent. 
Bolger et al 12 demonstrated in open labeled study 
conducted on 16 patients with systolic HF that intravenous 
iron replacement improves symptoms and exercise 
capacity. Toblli et al 19 demonstrated in a randomized 
study conducted on 40 patients with HF that intravenous 
iron therapy improves LVEF, NYHA functional class, 
exercise capacity and quality of life.  
Various mechanisms have been suggested for 
hemodynamic dysfunction and impaired exercise tolerance 
in patients with chronic HF.  Among them, inadequate 
oxygen supply and impaired oxygen utilization by skeletal 
muscle during exercise contribute to poor clinical status of 
HF patients20. In addition, anemia may aggravate 
symptoms in patients with HF.  Iron plays a key role in 
oxygen uptake, transport and storage as well as oxidative 
metabolism in the heart/ skeletal muscles. Iron has also 
been shown to be involved in erythropoiesis21.. Iron 
deficiency in patients with anemia attenuates aerobic 
performance and is associated with fatigue and exercise 
intolerance22. Iron replacement therapy in patients with 
iron deficiency without HF has been associated with 
improved exercise performance. Therefore, observed 
improvement in exercise tolerance, Borg dyspnoea and 
fatigue score and various haematological parameters in the 
present study may be explained on the basis of iron 
replacement therapy for 3 months. Since anemia results in 
reduced oxygen delivery to metabolizing tissues and 
causes dyspnoea, fatigue and edema, correction of anemia 
might be beneficial. Data showed that anemia can lead to 
eccentric hypertrophy in rat with increased capillary 
proliferation, abnormal diastolic wall stress and interstitial 
fibrosis23.  Levin et al 24 demonstrated that decrease in Hb 
concentration was found to be associated with an increase 
in left ventricular size.  Anand et al 25 reported that 1g/dl 
increase in Hb concentration over a 24 week period was 
associated with 4.1g/m2 decrease in left ventricular mass 
index. Erythropoietin treatment has also been shown to 
increase LVEF from 27 to 35 % after 7.2 months of 
treatment26.  Therefore, it is possible that iron 
supplementation as in our study may reduced ventricular 
hypertrophy and ultimately be responsible for improved 
LVEF.  Since anemia is associated with increased 
circulating TNF-α and cytokines (IL-6, IL-10 etc) 
activation ,iron supplementation might be beneficial in 
reducing TNF-α and cytokine levels. 
At present ,it is difficult to propose the exact molecular 
mechanism of beneficial effect of iron supplementation in 
patients of HF  with anemia but the study suggests 
favourable effects of oral iron therapy on exercise 
tolerance, quality of life, Borg dyspnoea and fatigue score 
and various haematological parameters. Further studies are 
required to elucidate other mechanisms of potential benefit 
of oral iron therapy in heart failure patients with anemia. 
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